

“High-achieving professional women, affluent holistic health advocates, and physically active women face significant challenges due to Premenstrual Syndrome (PMS) and menopause. These conditions can disrupt focus in high-stakes environments, diminish physical stamina, and strain public personas. Current solutions like hormonal control, psychiatric medications, PMS symptom relief, painkillers, and supplements often fall short. They can lead to side effects and lack a holistic, immediate response, leaving these women in search of an effective solution that aligns with their dynamic lifestyles and high-performance demands.

Addressing these gaps, La Miiel introduces its Intimate Serum, offering rapid relief from PMS and menopause symptoms. Made from natural ingredients, our serum efficiently alleviates these symptoms, enabling women to excel in their lives without PMS or menopausal discomforts. La Miiel Intimate Serum is more than a product; it's our commitment to empowering women during these challenging life phases.”

Registered PCT | Tested by olympic Athletes | margin: +90% | Customers: 50+ | Regulatory Approved

Business Model:

A wellness brand offering a natural, direct-to-consumer and subscription-based solution for women's intimate health, focusing on PMS and menopause relief.

Revenue Streams:

- Direct Product Sales
- Subscription Model
- Corporate Wellness Program Revenue
- Partnership with Women's Organizations for women in need (Diabetes, Cancer)

Corporate Detail:

Headquarter: New York

Production unit: South Korea

Staff: 5

Management and Founders:

[Jina Choi](#) (Chief Executive Officer)

[Elly Park](#) (Co Founder and Brand Developer)

Funding Ask:

Capital Sought: USD 2 Million.

Purpose: To expand La Miiel's product line, new products development, scale up production for various age groups, and obtain FDA approval while reducing costs.

Equity Offered: About 25% for a \$2 million on SAFE


Projected Outcomes: Targeting \$12 million annual income by Year 2.

Exit Strategy: Potential acquisition with a \$100 million valuation by Year 3, offering significant returns to early investors.

Value Proposition:

Natural PMS and Menopausal discomfort relief in hours, not weeks, women's best self without compromise.

Competitors:



Market:

TAM: USD 38.7 B (women's intimate health and wellness products)

SAM: USD 5.9 B (menopause and PMS treatment Annual expenditure in USA)

SOM: USD 12 Million (Our target revenue in year 2)

To reach this target we should have 11,000 Customers that use once per month our products.

Rigorous Testing:

We've conducted rigorous testing with Olympian athletes and armed forces personnel, subjecting our product to the most demanding conditions.

Investor Point of Contact:

You can contact us for more information and setting a meeting through Jina.Choi@lamiel.com